A study to evaluate safety, infectious risk and expansion with GCSF in patients with relapsed/refractory large B-cell lymphoma treated with Tisagenleuclecel or Axicabtagene-ciloleucel
Latest Information Update: 04 Aug 2021
At a glance
- Drugs Axicabtagene ciloleucel (Primary) ; Tisagenlecleucel (Primary) ; Granulocyte colony-stimulating factors
- Indications Non-Hodgkin's lymphoma
- Focus Adverse reactions
- 04 Aug 2021 New trial record
- 17 Jun 2021 Results presented at the 26th Congress of the European Haematology Association